HERCULES, Calif. - Bio-Rad Laboratories (NYSE:BIO), Inc. (NYSE: BIO and BIO.B), known for its life science research and clinical diagnostics products, announced the appointment of Jon DiVincenzo as the new President and Chief Operating Officer, effective September 9, 2024. He succeeds Andy Last, who is set to retire.
DiVincenzo's career spans over three decades in the industry with a focus on strategic, operational, and commercial roles. He comes to Bio-Rad from Labcorp Holdings Inc., where he served as Executive Vice President and President of Central Laboratories and International. His previous positions include President of the Environmental Health Division at PerkinElmer (NYSE:RVTY) and CEO of Enzymatics. DiVincenzo also held significant roles at EMD Millipore, a subsidiary of Merck KGaA. He is a mechanical engineering graduate from Northeastern University.
Norman Schwartz, Bio-Rad’s Chairman and CEO, expressed enthusiasm for DiVincenzo's appointment, citing his extensive experience and leadership in both life science and clinical diagnostics as vital to Bio-Rad's continued success.
In response to his new role, DiVincenzo shared his anticipation for contributing to Bio-Rad's long-term goals and transformational growth objectives.
Bio-Rad, headquartered in Hercules, California, operates globally with over 7,700 employees and reported revenues of $2.7 billion in 2023. The company provides a wide array of products and services to various customers including universities, research institutions, hospitals, and biopharmaceutical companies.
This executive transition is based on a press release statement from Bio-Rad Laboratories, Inc.
In other recent news, Bio-Rad Laboratories reported its second quarter 2024 financial results, meeting revenue expectations but revising its full-year outlook due to constraints in biotech and biopharma spending. Despite experiencing a decline in net sales, especially in the Life Science Group, the company registered an increase in gross margin and operating income. This was credited to cost control initiatives and a favorable product mix. Bio-Rad also announced an update on its leadership restructuring, including the search for a new Chief Operating Officer. The company has authorized an additional $500 million for share repurchases.
In terms of future plans, Bio-Rad has highlighted share repurchases and mergers and acquisitions as key strategies for creating shareholder value. The company is also preparing for the launch of a digital PCR product targeted for the fourth quarter of 2024. These are part of the recent developments within the company.
Analysts anticipate a recovery in the process chromatography segment by 2025. Despite the decline in sales, the Clinical Diagnostics Group shows steady growth. Furthermore, the digital PCR market is expected to remain stable with strength projected in the latter half of the year, according to company executives. These projections come from analysts at Wells Fargo, who are closely monitoring the company's progress.
InvestingPro Insights
As Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) welcomes Jon DiVincenzo to its executive team, investors and stakeholders may be interested in examining some key financial metrics and insights that could impact the company's performance. According to InvestingPro data, Bio-Rad has a market capitalization of approximately $9.1 billion, reflecting the company's significant presence in the life science and clinical diagnostics sectors. Despite a challenging period with revenue declining by 7.46% in the last twelve months as of Q2 2024, the company maintains a gross profit margin of 54.17%, indicating a strong ability to control costs and maintain profitability on its products and services.
InvestingPro Tips highlight that Bio-Rad's management has been actively engaged in share buybacks, which could signal confidence in the company's future prospects. Additionally, while Bio-Rad has not been profitable over the last twelve months, analysts predict the company will return to profitability this year. This forecast aligns with DiVincenzo's aim to contribute to Bio-Rad's transformational growth objectives and may reassure investors of the company's potential for improved financial performance.
Moreover, with liquid assets exceeding short-term obligations, Bio-Rad appears to have a solid liquidity position, which is crucial for sustaining operations and investing in future growth. It's also worth noting that the company does not pay a dividend, which could imply that it is reinvesting earnings back into the company to fuel its strategic initiatives and growth plans.
For those seeking a deeper dive into Bio-Rad's financials and future outlook, there are additional InvestingPro Tips available that provide further analysis and context. These tips can be accessed through the InvestingPro platform for a more comprehensive understanding of the company's financial health and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.